Acurx Pharmaceuticals, Inc. (ACXP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00510M2035
Acurx Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -8.09 m USD |
| EBIT | -8.09 m USD |
| Net income | -7.97 m USD |
| Diluted EPS – continuing operations | -5.32 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
More stocks
- Aprea Therapeutics, Inc. (APRE)
- Purple Innovation, Inc. (PRPL)
- GAXOS.AI INC. (GXAI)
- BAB, INC. (BABB)
- INTELLIGENT BIO SOLUTIONS INC. (INBS)
- Crypto Co (CRCW)
- Buildablock Corp. (NFTM)
- Royale Energy, Inc. (ROYL)
- American Picture House Corp (APHP)
- MGT CAPITAL INVESTMENTS, INC. (MGTI)
- ATHENA GOLD CORP (AHNRF)
- AIM ImmunoTech Inc. (AIM)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.